Lamb-scapers return to Conestoga College
For the second straight year, Conestoga College has enlisted the help of a flock of sheep to keep their solar panel fields neatly grazed.
This year's roster includes 35 sheep and 15 lambs.
'A lot of them were here last year so they understood right away when they got out of the trailer, where they were,' Tim Fisher, the sheep's shepherd, said. 'They were very excited to be here.'
They've once again been tasked with chewing away at the roughly three acres of land surrounding the school's solar arrays.
Instead of using gas-powered landscaping equipment such as lawn mowers, the flock offers an environmentally friendly alternative.
'We no longer need to use chemical herbicides or fertilizers,' explained Graham Aikenhead, associate director of sustainable automation and energy optimization at the college.
Officials estimate the project has reduced the school's herbicide use by approximately 60L and its fertilizer use by 160 kg.
This year, the flock is also providing an opportunity to forge connections.
'We've had classes out of the college. A bunch of instructors from the college have come in, staff, just to see what's going on,' Fisher said.
Another newly discovered perk stemming from the sheep's presence is re-naturalization in the area.
'We've noticed an increase in the number of insects and birds and other wildlife at the space,' said Aikenhead.
The wooly workers will be heading back home to All Sorts Acres Farm on Friday morning but will return to Conestoga for two weeks in July.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
National Post
2 hours ago
- National Post
Canada-UK Collaboration Developing AI-powered Bioreactors to Revolutionise Biopharmaceutical Manufacturing
Article content KITCHENER, Ontario & United Kingdom — An international initiative will transform biologics and drug manufacturing through AI-driven multiplatform integration. The AI-optimised BALANCE (Bioreactor Automation for Learning and Adaptive Networked Control of Experiments) platform will leverage Nicoya's real-time sensing and control systems, integrated with automation from Labman Automation, bioreactor technologies from CPI, and AI development by Basetwo to make bioprocessing smarter, more efficient, and faster. Article content The 20-month collaboration, led by Labman, is supported by a $2 million grant from Innovate UK and the National Research Council of Canada Industrial Research Assistance Program (NRC IRAP) through a Canada-UK Collaborative R&D initiative. The goal of the project is to deliver an AI-optimised demonstrator platform integrating bioreactor technologies with real-time sensing and control systems. It will leverage the joint expertise of the partners, bringing together the latest in AI, automation, and real-time process control to streamline upstream bioprocessing, ensuring higher yields, lower costs, and improved scalability for next-generation therapeutics. This aims to enhance the precision and efficiency of biologic drug production, offering a smarter, faster path to market. Article content Bioprocessing is an often-inefficient part of manufacturing that can slow down biopharma development. Optimizing bioprocessing requires making bioreactor operation more dynamic, relying on real-time data from biosensors. At the core of the BALANCE initiative is a closed-loop AI control system powered by Basetwo's digital twin platform. The machine learning models will interpret real-time data from the bioreactor and biosensors, enabling adaptive control of experimental conditions for real-time optimization of bioreactor performance. Labman will build an automated modular sampling platform that will automate molecular analysis, integrating seamlessly with Nicoya's Alto SPR biosensor for instant yield data and adaptive process control. Article content Basetwo's digital twin technology further enhances efficiency by predicting quality outcomes and reducing reliance on costly lab testing. CPI will validate and benchmark the system, ensuring practical scalability and commercial viability for biologics manufacturing. Article content This project marks a major step forward in digital bioprocessing, paving the way for increased efficiency, reduced variability, and faster time-to-market for breakthrough biologics. As an AI-driven testbed for next-generation model-based process control, the platform holds transformative potential for pharma and biotech industries striving for scalable, cost-effective production solutions. Article content 'Until now, sensing technology has been too slow and complex to enable truly reactive bioprocessing,' said Ryan Denomme, co-founder and CEO of Nicoya. 'Label-free biosensing is critical to unlocking the potential for automation and AI to drive efficiency in biomanufacturing, overcoming the complexity inherent in systems dealing with the diversity of living organisms. We look forward to working with our BALANCE partners to solve a bottleneck that can accelerate drug development.' Article content 'This is the next step for biologics and drug manufacturing, integrating Industry 4.0 approaches for bioprocessing,' said Thomas Smith, Head of Bioprocess Automation at Labman. 'By combining advanced sensing, AI and automation, we aim to accelerate process development, improve consistency, and create smarter, more efficient biomanufacturing workflows.' Article content Brendan Fish, Director of Biologics at CPI: 'Pharmaceutical companies know they must embrace digitalisation to stay competitive, but integrating digital technologies has been challenging in an industry that can be slow to evolve. Through collaboration, BALANCE is bridging this gap by validating and scaling AI-driven bioprocessing solutions to accelerate adoption and translate advancements into real-world impact for biologics manufacturing.' Article content 'AI-enabled digital twins is the next frontier in intelligent manufacturing,' said Thouheed Abdul Gaffoor, CEO at Basetwo. 'By combining our hybrid modelling approach with advanced sensing and automation, this collaboration moves us closer to autonomous biomanufacturing, cutting time, cost, and variability in producing life-saving therapeutics.' Article content About Nicoya Article content Nicoya is a Canadian life sciences tools company that specializes in biosensor technology. Its Alto Digital SPR platform delivers label-free, real-time biomolecular analysis, streamlining bioprocess development and monitoring. Article content About Labman Article content Labman Automation is a UK-based engineering company that designs and builds bespoke robotic systems and laboratory automation solutions. With a strong focus on flexibility, creativity, and engineering excellence, Labman helps customers across industries streamline operations and push the boundaries of what's possible in automated research and manufacturing. Article content About CPI Article content CPI catalyses the adoption of advanced technologies and manufacturing solutions to benefit people, places, and our planet. As part of the High Value Manufacturing Catapult, CPI helps accelerate innovation in HealthTech, pharma, AgriFoodTech, and beyond through world-class infrastructure and expertise. Article content About Basetwo Article content Basetwo is an AI platform helping process engineers in pharmaceutical and chemical manufacturing optimize operations using hybrid modelling. The platform provides engineers with recommendations on the next best action they can implement to maximize product quality, production yield, and process efficiency. Article content Article content Article content Article content Article content
National Post
3 hours ago
- National Post
Pramana Receives Health Canada Authorization for Digital Pathology Scanners
Article content CAMBRIDGE, Mass. — Pramana, an AI-enabled health tech company modernizing the pathology sector, today announced it has received Health Canada Medical Device Licenses for its flagship digital pathology scanners, the SpectralM and SpectralHT Cubiq systems. The approval authorizes Pramana to import, market, and sell its devices in Canada, expanding access to its advanced imaging and workflow solutions. Article content Health Canada authorization is required to commercialize Class II medical devices and affirms the product's safety, effectiveness, and quality. The approval opens the door for Pramana to support Canadian hospitals, pathology labs, and research institutions, helping modernize diagnostic workflows with scalable, AI-powered digital pathology tools. This recognition marks a critical step in Pramana's international expansion, building on its growing regulatory footprint. Article content 'Receiving Health Canada authorization is a major milestone in our commercialization strategy,' said Prasanth Perugupalli, Chief Product Officer at Pramana. 'It reflects the strength of our product development, quality, and regulatory readiness, and it opens the door to expanding access to our technology in a market known for strong clinical and academic institutions.' Article content Pramana's scanners are designed to digitize a wide range of pathology slides, producing high-resolution whole-slide images with automated quality control and AI-powered decision support. The platform supports both FFPE tissue and Liquid Based Cytology (LBC) samples prepared using methods such as the ThinPrep® Pap test (Hologic) and BD SurePath™ (Becton Dickinson). Unlike most digital pathology systems focused solely on anatomic pathology, Pramana expands digital workflows to include hematopathology, microbiology, and cytology, delivering flexibility across all major slide types. Article content 'Our research at the University of Toronto highlights the need for adaptable platforms that can manage these technical demands while still supporting routine histology and cytology workflows,' said Dr. Carlo Hojilla, Consultant Pathologist at the University of Toronto. 'Pramana's technology meets that standard, and its Health Canada authorization reflects both its clinical utility and the rigorous quality required for widespread adoption.' Article content Prior to receiving Health Canada authorization, Pramana secured Medical Device Single Audit Program (MDSAP) certification, a requirement that validated its quality management system and streamlined regulatory access in Canada, the United States, Brazil, Australia, and Japan, highlighting Pramana's commitment to modernizing digital pathology worldwide. Article content To discover how Pramana's whole-slide imaging solution can help healthcare organizations across Canada, visit Article content About Pramana, Inc. Article content Pramana is a health tech company transforming digital pathology with AI-powered imaging solutions that support seamless adoption across labs, health systems, and medical centers. Pramana's Spectral scanners deliver industry-leading image quality and unprecedented accuracy. Built-in AI algorithms and automated quality control streamline workflows, increase efficiency, and capture previously undetectable tissue features, empowering pathologists with the tools needed to improve clinical diagnostics and research. The company is headquartered in Cambridge, Mass. For more information, visit Article content Article content Article content Article content Article content Article content
Globe and Mail
4 hours ago
- Globe and Mail
NANO Nuclear Joins the Canadian Nuclear Association to Support the Adoption of Next-Generation Advanced Nuclear Energy Technologies in Canada
New York, New York--(Newsfile Corp. - July 24, 2025) - NANO Nuclear Energy Inc. (NASDAQ: NNE) ("NANO Nuclear" or "the Company"), a leading advanced nuclear energy and technology company focused on developing clean energy solutions, today announced that it has joined the Canadian Nuclear Association (CNA), the leading Canadian nuclear industry advocacy group since 1960. According to the CNA, every year in Canada, nuclear technology helps avoid 80 million tons of carbon dioxide emissions by displacing fossil fuels and supplies 50% of the global supply of cobalt-60, radioisotopes that are used to treat cancer and sterilize medical equipment, among other things. With the introduction of next-generation technologies in the form of small or micro nuclear reactors, like those being developed by NANO Nuclear, there is a significant opportunity for Canada to solidify a leading position in the global nuclear industry. "We're pleased to welcome NANO Nuclear Energy to the Canadian Nuclear Association. Their focus on advanced microreactor technologies aligns with Canada's growing leadership in innovative and scalable nuclear solutions. We look forward to supporting their engagement in the Canadian nuclear industry and working together to advance non-emitting, reliable, and secure energy for the future", said George Christidis, CEO and President Canadian Nuclear Association. Figure 1 - NANO Nuclear Energy Inc. Joins the Canadian Nuclear Association (CNA) and its Mission to Support the Development of Nuclear Energy Technologies in Canada, including Advanced Nuclear Energy Technologies. To view an enhanced version of this graphic, please visit: "We are proud to join the Canadian Nuclear Association and support its work to highlight the environmental, economic, and other benefits that nuclear technology brings to Canadians," said Jay Yu, Founder and Chairman of NANO Nuclear."Canada has shown strong commitment to advanced nuclear energy systems and is taking concrete steps toward deploying next-generation reactors like our KRONOS MMR TM, which are actively seeking to develop in Canada. This is an opportune time for NANO Nuclear to focus on our efforts to establish ourselves as the first North American commercially licensed microreactor technology company, and joining the CNA positions us to contribute to, and grow with, Canada's evolving energy landscape." NANO Nuclear has begun to lay the groundwork for site-specific engineering in preparation for bringing its lead microreactor project, the patented KRONOS MMR™ Energy System, to Canada and guiding it toward construction, testing and licensing. Alongside its U.S. progress, NANO Nuclear aims to renew its collaboration with Canadian Nuclear Laboratories and pursue the establishment of a KRONOS MMR™ demonstration site at Chalk River, Ontario, one of the leading hubs for nuclear energy expertise and engineering in Canada. NANO Nuclear further aims to foster technical leadership through strategic business relationships, and its membership in the CNA will enable NANO Nuclear to better position itself to support Canada's transition to the next generation of advanced nuclear energy systems. "The Canadian Nuclear Association is a leading voice in the nation's nuclear sector, and we're pleased to join the CNA and take an active role in advancing next generation technologies in Canada," said James Walker, Chief Executive Officer of NANO Nuclear."Strengthening ties with key policymakers and industry decision-makers is central to our goal of establishing NANO Nuclear as a global leader in advanced nuclear technology, including micro nuclear reactors. Our membership in the CNA broadens our insight into the Canadian market and positions us for next steps in the country, including establishing a demonstration site for the KRONOS MMR™ in Chalk River, Ontario, in conjunction with the Canadian Nuclear Laboratories and the Canadian Nuclear Safety Commission." About NANO Nuclear Energy, Inc. NANO Nuclear Energy Inc. (NASDAQ: NNE) is an advanced technology-driven nuclear energy company seeking to become a commercially focused, diversified, and vertically integrated company across five business lines: (i) cutting edge portable and other microreactor technologies, (ii) nuclear fuel fabrication, (iii) nuclear fuel transportation, (iv) nuclear applications for space and (v) nuclear industry consulting services. NANO Nuclear believes it is the first portable nuclear microreactor company to be listed publicly in the U.S. Led by a world-class nuclear engineering team, NANO Nuclear's reactor products in development include patented KRONOS MMR ™ Energy System, a stationary high-temperature gas-cooled reactor that is in construction permit pre-application engagement U.S. Nuclear Regulatory Commission (NRC) in collaboration with University of Illinois Urbana-Champaign (U. of I.), " ZEUS", a solid core battery reactor, and " ODIN", a low-pressure coolant reactor, and the space focused, portable LOKI MMR ™, each representing advanced developments in clean energy solutions that are portable, on-demand capable, advanced nuclear microreactors. Advanced Fuel Transportation Inc. (AFT), a NANO Nuclear subsidiary, is led by former executives from the largest transportation company in the world aiming to build a North American transportation company that will provide commercial quantities of HALEU fuel to small modular reactors, microreactor companies, national laboratories, military, and DOE programs. Through NANO Nuclear, AFT is the exclusive licensee of a patented high-capacity HALEU fuel transportation basket developed by three major U.S. national nuclear laboratories and funded by the Department of Energy. Assuming development and commercialization, AFT is expected to form part of the only vertically integrated nuclear fuel business of its kind in North America. HALEU Energy Fuel Inc. (HEF), a NANO Nuclear subsidiary, is focusing on the future development of a domestic source for a High-Assay, Low-Enriched Uranium (HALEU) fuel fabrication pipeline for NANO Nuclear's own microreactors as well as the broader advanced nuclear reactor industry. NANO Nuclear Space Inc. (NNS), a NANO Nuclear subsidiary, is exploring the potential commercial applications of NANO Nuclear's developing micronuclear reactor technology in space. NNS is focusing on applications such as the LOKI MMR ™ system and other power systems for extraterrestrial projects and human sustaining environments, and potentially propulsion technology for long haul space missions. NNS' initial focus will be on cis-lunar applications, referring to uses in the space region extending from Earth to the area surrounding the Moon's surface. For more corporate information please visit: For further NANO Nuclear information, please contact: Email: IR@ Business Tel: (212) 634-9206 PLEASE FOLLOW OUR SOCIAL MEDIA PAGES HERE: NANO Nuclear Energy LINKEDIN NANO Nuclear Energy YOUTUBE NANO Nuclear Energy X PLATFORM Cautionary Note Regarding Forward Looking Statements This news release and statements of NANO Nuclear's management in connection with this news release contain or may contain "forward-looking statements" within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. In this context, forward-looking statements mean statements related to future events, which may impact our expected future business and financial performance, and often contain words such as "expects", "anticipates", "intends", "plans", "believes", "potential", "will", "should", "could", "would" or "may" and other words of similar meaning. In this press release, forward-looking statements relate to the anticipated benefits to NANO Nuclear of its joining the CNA, as well as the Company's development plans for the KRONOS MMR TM in Canada. These and other forward-looking statements are based on information available to us as of the date of this news release and represent management's current views and assumptions. Forward-looking statements are not guarantees of future performance, events or results and involve significant known and unknown risks, uncertainties and other factors, which may be beyond our control. For NANO Nuclear, particular risks and uncertainties that could cause our actual future results to differ materially from those expressed in our forward-looking statements include but are not limited to the following: (i) risks related to our U.S. Department of Energy ("DOE") or related state or non-U.S. nuclear licensing submissions, (ii) risks related the development of new or advanced technology and the acquisition of complimentary technology or businesses, including difficulties with design and testing, cost overruns, regulatory delays, integration issues and the development of competitive technology, (iii) our ability to obtain contracts and funding to be able to continue operations, (iv) risks related to uncertainty regarding our ability to technologically develop and commercially deploy a competitive advanced nuclear reactor or other technology in the timelines we anticipate, if ever, (v) risks related to the impact of U.S. and non-U.S. government regulation, policies and licensing requirements, including by the DOE and the U.S. Nuclear Regulatory Commission, including those associated with the recently enacted ADVANCE Act and the May 23, 2025 Executive Orders seeking to streamline nuclear regulation, and (vi) similar risks and uncertainties associated with the operating an early stage business a highly regulated and rapidly evolving industry. Readers are cautioned not to place undue reliance on these forward-looking statements, which apply only as of the date of this news release. These factors may not constitute all factors that could cause actual results to differ from those discussed in any forward-looking statement, and NANO Nuclear therefore encourages investors to review other factors that may affect future results in its filings with the SEC, which are available for review at and at Accordingly, forward-looking statements should not be relied upon as a predictor of actual results. We do not undertake to update our forward-looking statements to reflect events or circumstances that may arise after the date of this news release, except as required by law.
